Browse the evidence

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

There were no between-group differences in body composition and adaptive thermogenesis.

Practitioners should note that both diets did not significantly affect body composition or thermogenesis.

In the intensive lifestyle intervention group, higher variability of BMI is not associated with increased risks of all-cause mortality, cardiovascular deaths, or cardiovascular events.

Intensive lifestyle interventions may mitigate the risks associated with BMI variability in patients with type 2 diabetes.

There were no significant changes in HbA1c between year 1 and year 4 for all bMVPA timing groups.

Practitioners should be aware that initial improvements in glycemic control may not persist long-term.

Sleeve gastrectomy has emerged as the most popular bariatric procedure in the last 10 years.

Surgeons should be aware that sleeve gastrectomy is currently the preferred option among patients.

Patients who had bariatric surgery for morbid obesity after liver transplantation had a 16% post-bariatric surgery major complication rate.

Caution is advised for patients undergoing bariatric surgery after liver transplantation due to a higher complication rate.

The need for more effective treatments for obesity is obvious due to the far-reaching effects of the condition.

Healthcare providers should prioritize finding effective obesity treatments.

30% of steep losers died during postintervention follow-up versus 10-18% in other trajectories.

Monitoring for excessive weight loss is crucial, especially in older adults with diabetes.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Individuals with Friedreich's ataxia (FRDA) have lower insulin sensitivity (whole-body insulin sensitivity index 2.8 vs 5.3, P < .01) compared to controls.

Practitioners should be aware that FRDA is associated with reduced insulin sensitivity, which may impact metabolic health.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.

Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.

Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.

Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.

Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.

Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.

Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.

Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.

Liraglutide may not affect muscle or bone mass in the short term.

SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties.

SGLT-2 inhibitors may be beneficial for patients with diabetes and related complications.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

GC ablation in mice fed a high fat diet protects against obesity and type 2 diabetes.

This suggests that targeting GC could be beneficial in preventing obesity in high-fat diet scenarios.

Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).

This suggests that addressing demographic and comorbid factors may improve weight loss outcomes in T2D patients.

No significant differences in metabolic flexibility were observed between the RE+CON and RE+PRO groups.

Combining resistance exercise with either a control or high protein diet does not significantly alter metabolic flexibility outcomes.

MetFlex to fat showed no correlation to MetFlex measured during the clamp.

Different methods may yield different insights into metabolic flexibility.

For each one percent reduction in body weight at eight weeks, there was a 112.6 μmoL/l increase in fasting beta-hydroxybutyrate concentrations.

Weight loss is associated with increased ketone production, which may aid in understanding dietary interventions.